ArticleFrontiers in immunology2026
Immuno-based profiling of knee osteoarthritis patients identifies baseline characteristics associated with positive response to autologous platelet-rich plasma injection at one-year follow-up.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarthritis (OA) is a degenerative musculoskeletal disease of multifactorial origin causing chronic disability, despite numerous treatment options for which there are no predictive biomarkers on the different endotypes. We aimed at defining a peripheral blood (PB) profile potentially predictive of early and sustained response to intra-articular injection of autologous platelet-rich plasma (PRP). Methods: A prospective study was conducted on male and female patients aged 40-74 years, with Kellgren-Lawrence knee OA grade 2-3 candidates to PRP injection. PB was obtained from patients at enrollment prior to PRP injection to assess immune phenotype of PBMCs with multiparametric flow cytometry; serum antioxidant capacity; PBMC expression of molecules involved in inflammatory pathways; serum concentrations of related inflammatory cytokines and chemokines. After one year of follow-up, response was defined based on WOMAC questionnaires and clinical criteria and correlated with the immune profile. Results: Among 109 enrolled patients, 60 had early and sustained response to treatment and 49 were non-responders, irrespective of age, sex, and previous conservative therapy or surgery. Responders had lower oxidative stress and a peculiar profile of inflammatory markers (higher CD40L, Eotaxin 1; G-CSF, GROα, MIP3b, and PD-L1; lower TNFα, PTX3, and PDGF-AA) and immune cell composition (higher circulating CD14 Discussion: We describe an immunophenotype associated with early and sustained response to PRP treatment in knee OA and submit that this may be candidate to validation for predicting clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.